358 related articles for article (PubMed ID: 30372397)
1. Chromosome 3p Loss-Orchestrated VHL, HIF, and Epigenetic Deregulation in Clear Cell Renal Cell Carcinoma.
Hsieh JJ; Le VH; Oyama T; Ricketts CJ; Ho TH; Cheng EH
J Clin Oncol; 2018 Oct; 36(36):JCO2018792549. PubMed ID: 30372397
[TBL] [Abstract][Full Text] [Related]
2. PBRM1 and BAP1 as novel targets for renal cell carcinoma.
Brugarolas J
Cancer J; 2013; 19(4):324-32. PubMed ID: 23867514
[TBL] [Abstract][Full Text] [Related]
3. Involvement of PBRM1 in VHL disease-associated clear cell renal cell carcinoma and its putative relationship with the HIF pathway.
Gad S; Le Teuff G; Nguyen B; Verkarre V; Duchatelle V; Molinie V; Posseme K; Grandon B; Da Costa M; Job B; Meurice G; Droin N; Mejean A; Couve S; Renaud F; Gardie B; Teh BT; Richard S; Ferlicot S
Oncol Lett; 2021 Dec; 22(6):835. PubMed ID: 34712359
[TBL] [Abstract][Full Text] [Related]
4. Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma.
Gossage L; Murtaza M; Slatter AF; Lichtenstein CP; Warren A; Haynes B; Marass F; Roberts I; Shanahan SJ; Claas A; Dunham A; May AP; Rosenfeld N; Forshew T; Eisen T
Genes Chromosomes Cancer; 2014 Jan; 53(1):38-51. PubMed ID: 24166983
[TBL] [Abstract][Full Text] [Related]
5. Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status.
Messai Y; Gad S; Noman MZ; Le Teuff G; Couve S; Janji B; Kammerer SF; Rioux-Leclerc N; Hasmim M; Ferlicot S; Baud V; Mejean A; Mole DR; Richard S; Eggermont AM; Albiges L; Mami-Chouaib F; Escudier B; Chouaib S
Eur Urol; 2016 Oct; 70(4):623-632. PubMed ID: 26707870
[TBL] [Abstract][Full Text] [Related]
6. Suppressive effects of iron chelation in clear cell renal cell carcinoma and their dependency on VHL inactivation.
Greene CJ; Sharma NJ; Fiorica PN; Forrester E; Smith GJ; Gross KW; Kauffman EC
Free Radic Biol Med; 2019 Mar; 133():295-309. PubMed ID: 30553971
[TBL] [Abstract][Full Text] [Related]
7. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.
Hakimi AA; Chen YB; Wren J; Gonen M; Abdel-Wahab O; Heguy A; Liu H; Takeda S; Tickoo SK; Reuter VE; Voss MH; Motzer RJ; Coleman JA; Cheng EH; Russo P; Hsieh JJ
Eur Urol; 2013 May; 63(5):848-54. PubMed ID: 23036577
[TBL] [Abstract][Full Text] [Related]
8. Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesis.
Wang SS; Gu YF; Wolff N; Stefanius K; Christie A; Dey A; Hammer RE; Xie XJ; Rakheja D; Pedrosa I; Carroll T; McKay RM; Kapur P; Brugarolas J
Proc Natl Acad Sci U S A; 2014 Nov; 111(46):16538-43. PubMed ID: 25359211
[TBL] [Abstract][Full Text] [Related]
9. Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma.
Bihr S; Ohashi R; Moore AL; Rüschoff JH; Beisel C; Hermanns T; Mischo A; Corrò C; Beyer J; Beerenwinkel N; Moch H; Schraml P
Neoplasia; 2019 Feb; 21(2):247-256. PubMed ID: 30660076
[TBL] [Abstract][Full Text] [Related]
10. BAP1-Mutated Clear Cell Renal Cell Carcinoma.
Gallan AJ; Parilla M; Segal J; Ritterhouse L; Antic T
Am J Clin Pathol; 2021 Apr; 155(5):718-728. PubMed ID: 33210135
[TBL] [Abstract][Full Text] [Related]
11. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
[TBL] [Abstract][Full Text] [Related]
12. BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies.
Piva F; Santoni M; Matrana MR; Satti S; Giulietti M; Occhipinti G; Massari F; Cheng L; Lopez-Beltran A; Scarpelli M; Principato G; Cascinu S; Montironi R
Expert Rev Mol Diagn; 2015; 15(9):1201-10. PubMed ID: 26166446
[TBL] [Abstract][Full Text] [Related]
13. The epigenetic landscape of clear-cell renal cell carcinoma.
Kluzek K; Bluyssen HA; Wesoly J
J Kidney Cancer VHL; 2015; 2(3):90-104. PubMed ID: 28326264
[TBL] [Abstract][Full Text] [Related]
14. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.
Hakimi AA; Ostrovnaya I; Reva B; Schultz N; Chen YB; Gonen M; Liu H; Takeda S; Voss MH; Tickoo SK; Reuter VE; Russo P; Cheng EH; Sander C; Motzer RJ; Hsieh JJ;
Clin Cancer Res; 2013 Jun; 19(12):3259-67. PubMed ID: 23620406
[TBL] [Abstract][Full Text] [Related]
15. Loss of PBRM1 expression is associated with renal cell carcinoma progression.
Pawłowski R; Mühl SM; Sulser T; Krek W; Moch H; Schraml P
Int J Cancer; 2013 Jan; 132(2):E11-7. PubMed ID: 22949125
[TBL] [Abstract][Full Text] [Related]
16. The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma.
Nargund AM; Pham CG; Dong Y; Wang PI; Osmangeyoglu HU; Xie Y; Aras O; Han S; Oyama T; Takeda S; Ray CE; Dong Z; Berge M; Hakimi AA; Monette S; Lekaye CL; Koutcher JA; Leslie CS; Creighton CJ; Weinhold N; Lee W; Tickoo SK; Wang Z; Cheng EH; Hsieh JJ
Cell Rep; 2017 Mar; 18(12):2893-2906. PubMed ID: 28329682
[TBL] [Abstract][Full Text] [Related]
17. Targeting renal cell carcinoma with a HIF-2 antagonist.
Chen W; Hill H; Christie A; Kim MS; Holloman E; Pavia-Jimenez A; Homayoun F; Ma Y; Patel N; Yell P; Hao G; Yousuf Q; Joyce A; Pedrosa I; Geiger H; Zhang H; Chang J; Gardner KH; Bruick RK; Reeves C; Hwang TH; Courtney K; Frenkel E; Sun X; Zojwalla N; Wong T; Rizzi JP; Wallace EM; Josey JA; Xie Y; Xie XJ; Kapur P; McKay RM; Brugarolas J
Nature; 2016 Nov; 539(7627):112-117. PubMed ID: 27595394
[TBL] [Abstract][Full Text] [Related]
18. The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer.
Liao L; Testa JR; Yang H
Cancer Genet; 2015 May; 208(5):206-14. PubMed ID: 25873528
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and Predictive Value of
Carril-Ajuria L; Santos M; Roldán-Romero JM; Rodriguez-Antona C; de Velasco G
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31861590
[TBL] [Abstract][Full Text] [Related]
20. Epigenome Aberrations: Emerging Driving Factors of the Clear Cell Renal Cell Carcinoma.
Mehdi A; Riazalhosseini Y
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28812986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
